CN101732340B - 一种花蕊石提取物的用途及制备方法 - Google Patents
一种花蕊石提取物的用途及制备方法 Download PDFInfo
- Publication number
- CN101732340B CN101732340B CN 201010010027 CN201010010027A CN101732340B CN 101732340 B CN101732340 B CN 101732340B CN 201010010027 CN201010010027 CN 201010010027 CN 201010010027 A CN201010010027 A CN 201010010027A CN 101732340 B CN101732340 B CN 101732340B
- Authority
- CN
- China
- Prior art keywords
- ophicalcitum
- extract
- serpentine
- preparing
- cancer therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000284 extract Substances 0.000 title claims abstract description 34
- 238000000034 method Methods 0.000 title claims abstract description 20
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 claims abstract description 33
- 239000003814 drug Substances 0.000 claims abstract description 25
- 230000001093 anti-cancer Effects 0.000 claims abstract description 12
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 11
- 239000011707 mineral Substances 0.000 claims abstract description 11
- 239000000843 powder Substances 0.000 claims abstract description 10
- 239000011435 rock Substances 0.000 claims abstract description 7
- 238000000338 in vitro Methods 0.000 claims abstract description 4
- 238000001727 in vivo Methods 0.000 claims abstract description 3
- 239000002245 particle Substances 0.000 claims abstract description 3
- 239000007788 liquid Substances 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000000835 fiber Substances 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- 238000011275 oncology therapy Methods 0.000 claims description 8
- 239000013078 crystal Substances 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 claims description 3
- 239000006286 aqueous extract Substances 0.000 claims description 3
- 239000012567 medical material Substances 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 239000008367 deionised water Substances 0.000 claims description 2
- 229910021641 deionized water Inorganic materials 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 238000005070 sampling Methods 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 201000008275 breast carcinoma Diseases 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000032696 parturition Effects 0.000 claims 1
- 238000011160 research Methods 0.000 abstract description 4
- 239000002121 nanofiber Substances 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract 2
- 239000004579 marble Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 8
- 208000014018 liver neoplasm Diseases 0.000 description 8
- 239000011777 magnesium Substances 0.000 description 8
- 230000001629 suppression Effects 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 201000007270 liver cancer Diseases 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229910052599 brucite Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- 229910021532 Calcite Inorganic materials 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910002656 O–Si–O Inorganic materials 0.000 description 1
- 229910004283 SiO 4 Inorganic materials 0.000 description 1
- 229910002808 Si–O–Si Inorganic materials 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001644 anti-hepatocarcinoma Effects 0.000 description 1
- 229910052898 antigorite Inorganic materials 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 229910052620 chrysotile Inorganic materials 0.000 description 1
- 229910052956 cinnabar Inorganic materials 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- -1 dimethyl sulfoxine Chemical compound 0.000 description 1
- 239000010459 dolomite Substances 0.000 description 1
- 229910000514 dolomite Inorganic materials 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000001257 hydrogen Chemical group 0.000 description 1
- 229910052739 hydrogen Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 201000009442 piebaldism Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- CWBIFDGMOSWLRQ-UHFFFAOYSA-N trimagnesium;hydroxy(trioxido)silane;hydrate Chemical compound O.[Mg+2].[Mg+2].[Mg+2].O[Si]([O-])([O-])[O-].O[Si]([O-])([O-])[O-] CWBIFDGMOSWLRQ-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010010027 CN101732340B (zh) | 2010-01-06 | 2010-01-06 | 一种花蕊石提取物的用途及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010010027 CN101732340B (zh) | 2010-01-06 | 2010-01-06 | 一种花蕊石提取物的用途及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101732340A CN101732340A (zh) | 2010-06-16 |
CN101732340B true CN101732340B (zh) | 2012-12-05 |
Family
ID=42456709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201010010027 Expired - Fee Related CN101732340B (zh) | 2010-01-06 | 2010-01-06 | 一种花蕊石提取物的用途及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101732340B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107510702A (zh) * | 2017-10-20 | 2017-12-26 | 陈键 | 一种青礞石提取物的制备方法及用途 |
CN108524629A (zh) * | 2018-05-25 | 2018-09-14 | 佛山汇沐化学科技有限公司 | 一种止血化瘀膏及其制备方法 |
CN113952462B (zh) * | 2021-11-18 | 2023-07-21 | 中南大学湘雅三医院 | 合成类纤维蛇纹石纳米材料的用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101342189A (zh) * | 2008-08-28 | 2009-01-14 | 浙江大学 | 外用花蕊石复合物紧急救生止血剂的制备方法 |
-
2010
- 2010-01-06 CN CN 201010010027 patent/CN101732340B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101342189A (zh) * | 2008-08-28 | 2009-01-14 | 浙江大学 | 外用花蕊石复合物紧急救生止血剂的制备方法 |
Non-Patent Citations (2)
Title |
---|
沈坚等."一种止血良药——花蕊石止血散".《中成药研究》.1985,(第8期),第42页. |
陈惠霞等."花蕊石炮制与疗效关系".《吉林中医药》.1996,(第4期),第36页. |
Also Published As
Publication number | Publication date |
---|---|
CN101732340A (zh) | 2010-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103880910A (zh) | 一种环黄芪醇的制备方法及其用途 | |
CN101732340B (zh) | 一种花蕊石提取物的用途及制备方法 | |
JP2017518381A (ja) | 瓦草5環性トリテルペンサポニン類化合物抗腫瘍の薬物用途 | |
CN101671319A (zh) | 红豆杉无毒提取物的工艺 | |
CN102475698B (zh) | 丹酚酸l在制备治疗肿瘤药物中的应用 | |
CN101732564B (zh) | 一种用于抗癌的中药组合物、其制备方法和应用 | |
CN101624387B (zh) | 一种异土木香内酯的提纯制备方法和其在制备抗肿瘤药物中的应用 | |
CN102030800B (zh) | 杉松三萜类化合物及其提取分离与应用 | |
CN103893412B (zh) | 一种抗肿瘤裸花紫珠提取物及其制备方法和用途 | |
CN101791363A (zh) | 一种广谱抗癌植物药、其制备方法及其应用 | |
CN1237985C (zh) | 治疗肿瘤的中药注射制剂及其制作方法 | |
CN102160863B (zh) | 一种异土木香内酯的提纯制备方法和其在制备抗肿瘤药物中的应用 | |
CN103239470A (zh) | 一种含鸡腿蘑多糖和香菇多糖的双菇多糖组合物及其制法和用途 | |
CN102688248A (zh) | 蟾蜍甾烯类化合物在制备治疗口腔黏膜恶性肿瘤药物中的应用 | |
CN103610849B (zh) | 仁青常觉在制备治疗前列腺癌药物中的应用 | |
CN102727867B (zh) | 一种抗肿瘤用药物组合物及应用、试剂盒及包装件 | |
CN101120958B (zh) | 一种治疗肝癌、白血病的药物制剂与其生产工艺 | |
CN101062040B (zh) | 稳定型葫芦素液体组方及其制剂 | |
CN103623144B (zh) | 仁青常觉在制备治疗卵巢癌药物中的应用 | |
CN103655822B (zh) | 一种抗肿瘤药物、制备方法及其用途 | |
CN102836315A (zh) | 一种预防调理转归肿瘤的中药组合物及其制备方法 | |
CN107019771A (zh) | 一种抗肿瘤的中药组合物 | |
CN102579756B (zh) | 含有穿山龙提取物与哈尔满碱及哈尔满碱类衍生物的药物组合物及其应用 | |
CN102100836B (zh) | 一种治疗肿瘤的药物组合物及其制备方法和用途 | |
CN104840727B (zh) | 具有抗食道癌活性的中药组合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SHENYANG OASIS PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: LIAONING UNIVERSITY OF TCM Effective date: 20120625 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 110032 SHENYANG, LIAONING PROVINCE TO: 110016 SHENYANG, LIAONING PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20120625 Address after: The young street in Shenhe District of Shenyang city in Liaoning province 110016 A Gallery Plaza 165-9 block 19 layer Applicant after: SHENZHEN OASIS PHARMACEUTICAL CO.,LTD. Address before: Huanggu District of Shenyang City, 110032 East Road, located in Liaoning province No. 79 scientific research department of Liaoning University of Traditional Chinese Medicine Applicant before: LIAONING University OF TRADITIONAL CHINESE MEDICINE |
|
ASS | Succession or assignment of patent right |
Owner name: YU XIANG Free format text: FORMER OWNER: SHENYANG OASIS PHARMACEUTICAL CO., LTD. Effective date: 20120929 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 110016 SHENYANG, LIAONING PROVINCE TO: 110000 SHENYANG, LIAONING PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20120929 Address after: 110000 1-5-2, 27 Xuzhou street, Heping District, Liaoning, Shenyang Applicant after: Yu Xiang Address before: The young street in Shenhe District of Shenyang city in Liaoning province 110016 A Gallery Plaza 165-9 block 19 layer Applicant before: SHENZHEN OASIS PHARMACEUTICAL CO.,LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121205 Termination date: 20220106 |